Why the study?
Concerns existed that occasional cross-inoculation with different commercial FMD vaccines might induce a poor immune response by failing to boost immunity in fattening pigs.
Does heterologous prime-boost vaccination improve immune response compared to homologous vaccination in pigs?
Does heterologous prime-boost vaccination improve immune response compared to homologous vaccination in pigs?
Heterologous prime-boost vaccination with commercial FMD vaccines in pigs enhances broader cross-reactivity without hampering the primary immune response.
May support heterologous prime-boost FMD regimens in pigs; leaves open translation to field use or other species.
Three commercial vaccines are administered in domestic livestock farms for routine vaccination to aid for foot-and-mouth disease (FMD) control in Korea. Each vaccine contains distinct combinations of inactivated serotype O and A FMD virus (FMDV) antigens: O/Manisa + O/3039 + A/Iraq formulated in a double oil emulsion (DOE), O/Primorsky + A/Zabaikalsky formulated in a DOE, and O/Campos + A/Cruzeiro + A/2001 formulated in a single oil emulsion. Despite the recommendation for a prime-boost vaccination with the same vaccine in fattening pigs, occasional cross-inoculation is inevitable for many reasons, such as lack of compliance with vaccination guidelines, erroneous application, or change in vaccine types by suppliers. Therefore, there have been concerns that a poor immune response could be induced by cross-inoculation due to a failure to boost the immune response. In the present study, it was demonstrated by virus neutralization and ELISA tests that cross-inoculation of pigs with three commercial FMD vaccines does not hamper the immune response against the primary vaccine strains and enhances broader cross-reactivity against heterologous vaccine antigens whether they were applied or not. Therefore, it could be concluded that the cross-inoculation of FMD vaccines can be used as a regimen to strategically overcome the limitation of the antigenic spectrum induced by the original regimen.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: